.jpg "Halozyme (NASDAQ: HALO)")
Today, a Major Shareholder at Halozyme (NASDAQ: HALO), Randal Kirk, sold shares of HALO for $9.94M.
See today’s analyst top recommended stocks >>
Based on Halozyme’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $35.2 million and GAAP net loss of $22.89 million. In comparison, last year the company earned revenue of $33.75 million and had a GAAP net loss of $30.76 million. HALO’s market cap is $2.5B and the company has a P/E ratio of 33.37. Currently, Halozyme has an average volume of 1.25M.
Based on 3 analyst ratings, the analyst consensus is Hold with an average price target of $20.33, reflecting a -16.4% downside.
The insider sentiment on Halozyme has been negative according to 22 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.
